Umlobi: William Ramirez
Usuku Lokudalwa: 16 Usepthemba 2021
Ukuvuselela Usuku: 12 Agasti 2025
Anonim
What Doctors are saying about CBD? | Cannabidiol
Ividiyo: What Doctors are saying about CBD? | Cannabidiol

-Delile

I-Cannabidiol iyikhemikhali esitshalweni se-Cannabis sativa, esaziwa nangokuthi insangu noma i-hemp. Ngaphezulu kwamakhemikhali angama-80, aziwa ngama-cannabinoids, akhonjwe esitshalweni seCannabis sativa. Ngenkathi i-delta-9-tetrahydrocannabinol (iTHC) iyisithako esiyinhloko sentsangu, i-cannabidiol nayo itholakala ku-hemp, equkethe amanani amancane kakhulu we-THC.

Ukudluliswa koMthethosivivinywa weFama i-2018 wakwenza kwaba semthethweni ukuthengisa imikhiqizo ye-hemp ne-hemp e-U.S. Kodwa lokho akusho ukuthi yonke imikhiqizo etholakala nge-hemp ye-cannabidiol isemthethweni. Njengoba i-cannabidiol ifundwe njengomuthi omusha, ayikwazi ukufakwa ngokusemthethweni ekudleni noma kwizithasiselo zokudla. Futhi, i-cannabidiol ayikwazi ukufakwa emikhiqizweni emakethwa ngezimangalo zokwelapha. ICannabidiol ingafakwa kuphela kwimikhiqizo "yezimonyo" futhi kuphela uma iqukethe ngaphansi kuka-0.3% THC. Kepha kusekhona imikhiqizo enelebula njengezithako zokudla emakethe equkethe i-cannabidiol. Inani le-cannabidiol eliqukethwe kule mikhiqizo alihlali libikwa ngokunembile kwilebula yomkhiqizo.

I-Cannabidiol ijwayele ukusetshenziselwa ukugula (isithuthwane). Ibuye isetshenziselwe ukukhathazeka, ubuhlungu, ukuphazamiseka kwemisipha okubizwa nge-dystonia, isifo se-Parkinson, isifo se-Crohn, nezinye izimo eziningi, kepha abukho ubufakazi obuhle besayensi bokusekela lokhu kusetshenziswa.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze I-CANNABIDIOL (CBD) zimi kanje:


Cishe iyasebenza ...

  • Isifo sokuquleka (isithuthwane). Umkhiqizo othile we-cannabidiol (i-Epidiolex, i-GW Pharmaceuticals) ukhonjisiwe ukunciphisa ukubanjwa kwabantu abadala nezingane ezinezimo ezahlukahlukene ezixhumene nokuquleka. Lo mkhiqizo umuthi kadokotela wokwelapha ukuquleka okubangelwa i-Dravet syndrome, i-Lennox-Gastaut syndrome, noma i-tuberous sclerosis complex. Kubuye kwakhonjiswa ukunciphisa ukwehliswa kwabantu abane-Sturge-Weber syndrome, i-febrile-related-epilepsy syndrome (i-FIRES), kanye nokuphazamiseka okuthile kwezofuzo okubangela i-encephalopathy yesithuthwane. Kodwa akuvunyelwe ukwelapha lezi ezinye izinhlobo zokubamba. Lo mkhiqizo uvame ukuthathwa uhlanganiswe nemithi ejwayelekile yokulwa nokuquleka. Eminye imikhiqizo ye-cannabidiol eyenziwe elebhu nayo ifundelwa isifo sokuwa. Kepha ucwaningo lukhawulelwe, futhi awukho nowodwa wale mikhiqizo ovunyelwe njengemithi kadokotela.

Ubufakazi obanele bokukala ukusebenza kwe ...

  • Uhlobo lwesifo samathumbu esivuthayo (isifo seCrohn). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-cannabidiol akukunciphisi ukusebenza kwezifo kubantu abadala abanesifo seCrohn.
  • Isifo sikashukela. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-cannabidiol akukuthuthukisi abantu abadala abalawula i-glucose egazini abane-type 2 diabetes.
  • Ukuphazamiseka kokuhamba okuphawulwe ngokuncipha kwemisipha okungazibandakanyi (i-dystonia). Akucaci ukuthi i-cannabidiol iyazuzisa yini i-dystonia.
  • Isimo esizuzwe njengefa esimakwe ukukhubazeka kokufunda (i-fragile- X syndrome). Ucwaningo lwakuqala luphakamisa ukuthi ukusebenzisa ijeli ye-cannabidiol kunganciphisa ukukhathazeka futhi kuthuthukise indlela yokuziphatha ezinganeni ezine-X syndrome ebuthaka.
  • Isimo lapho ukufakelwa kabusha kuhlasela umzimba (isifo se-graft-versus-host noma i-GVHD). Isifo se-Graft-versus-host siyinkinga engenzeka ngemuva kokufakelwa komnkantsha wethambo. Ucwaningo lwakuqala luthole ukuthi ukuthatha i-cannabidiol nsuku zonke ukuqala ezinsukwini eziyi-7 ngaphambi kokufakelwa komnkantsha wethambo nokuqhubeka izinsuku ezingama-30 ngemuva kokufakelwa kungandisa isikhathi esithathayo kumuntu ukwenza i-GVHD.
  • Isifo sobuchopho esizuze njengefa esithinta ukunyakaza, imizwa nokucabanga (Isifo sikaHuntington). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-cannabidiol nsuku zonke akuzithuthukisi izimpawu zesifo sikaHuntington.
  • I-Multiple sclerosis (MS). Ucwaningo lwakuqala luphakamisa ukuthi ukusebenzisa i-cannabidiol spray ngaphansi kolimi kungathuthukisa ubuhlungu nokuqina kwemisipha kubantu abane-MS.
  • Ukuhoxa kwi-heroin, morphine, nezinye izidakamizwa ze-opioid. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-cannabidiol izinsuku ezintathu kunganciphisa izifiso nokukhathazeka kubantu abanenkinga yokusebenzisa i-heroin.
  • Isifo se-Parkinson. Ucwaningo lwakuqala lukhombisa ukuthi i-cannabidiol inganciphisa ukukhathazeka nezimpawu zengqondo kubantu abanesifo sikaParkinson.
  • Ischizophrenia. Ucwaningo lokuqala lubonisa ukuthi ukuthatha i-cannabidiol kuthuthukisa izimpawu nokuphila kahle kubantu abane-schizophrenia.
  • Ukuyeka ukubhema. Ucwaningo lwakuqala luphakamisa ukuthi ukuhogela i-cannabidiol nge-inhaler isonto elilodwa kunganciphisa isibalo sogwayi ababhenywa ababhemayo abazama ukuyeka.
  • Uhlobo lokukhathazeka olubhalwe ukwesaba kwezinye noma kuzo zonke izilungiselelo zomphakathi (ukuphazamiseka kokukhathazeka komphakathi). Ucwaningo lwakuqala lukhombisa ukuthi i-cannabidiol ingahle ithuthukise ukukhathazeka kubantu abanalesi sifo. Kodwa akucaci ukuthi kuyasiza yini ukunciphisa ukukhathazeka ngesikhathi sokukhuluma phambi kwabantu.
  • Iqembu lezimo ezibuhlungu ezithinta ukuhlangana komhlathi nemisipha (izifo ze-temporomandibular noma i-TMD). Ucwaningo lwakuqala lukhombisa ukuthi ukusebenzisa uwoyela oqukethe i-cannabidiol esikhunjeni kunganciphisa ubuhlungu kubantu abane-TMD.
  • Ukulimala kwemithambo ezandleni nasezinyaweni (i-peripheral neuropathy).
  • Ukuphazamiseka kwe-bipolar.
  • Ukuqwasha.
  • Ezinye izimo.
Kudingeka ubufakazi obuningi ukukala ukusebenza kwe-cannabidiol kulokhu kusetshenziswa.

I-Cannabidiol inemiphumela ebuchosheni. Imbangela ngqo yale miphumela ayicaci. Kodwa-ke, i-cannabidiol ibonakala ivimbela ukuwohloka kwekhemikhali ebuchosheni ethinta izinhlungu, imizwa nokusebenza kwengqondo. Ukuvimbela ukuwohloka kwaleli khemikhali nokwandisa amazinga alo egazini kubonakala kunciphisa izimpawu zengqondo ezihambisana nezimo ezifana ne-schizophrenia. ICannabidiol ingahle futhi ivimbele eminye yemiphumela yokusebenza kwengqondo ye-delta-9-tetrahydrocannabinol (THC). Futhi, i-cannabidiol ibonakala inciphisa ubuhlungu nokukhathazeka.

Lapho ithathwa ngomlomo: ICannabidiol OKUNGENZEKA UKUPHEPHA lapho ithathwa ngomlomo noma ifuthwe ngaphansi kolimi ngokufanele. I-Cannabidiol ngemithamo efinyelela ku-300 mg nsuku zonke ithathwe ngomlomo ngokuphepha izinyanga ezi-6. Imithamo ephakeme ye-1200-1500 mg nsuku zonke ithathwe ngomlomo ngokuphepha kuze kube amasonto ama-4. Umkhiqizo kadokotela we-cannabidiol (i-Epidiolex) uvunyelwe ukuthi uthathwe ngomlomo ngemithamo efinyelela kuma-25 mg / kg nsuku zonke. Izifutho zeCannabidiol ezisetshenziswa ngaphansi kolimi zisetshenziswe ngemithamo ye-2.5 mg amasonto angafika kwamabili.

Eminye imiphumela emibi ebikiwe ye-cannabidiol ifaka phakathi umlomo owomile, umfutho ophansi wegazi, ukukhanyisa okukhanyayo, kanye nokozela. Izimpawu zokulimala kwesibindi nazo zibikiwe kwezinye iziguli, kepha lokhu akuvamile.

Lapho isetshenziswa esikhunjeni: Alukho ulwazi olwanele oluthembekile lokwazi ukuthi i-cannabidiol iphephile yini noma yini imiphumela emibi engaba yiyo.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: ICannabidiol MHLAWUMBI ANGIPHEPHILE ukusebenzisa uma ukhulelwe noma uncelisa ibele. Imikhiqizo yeCannabidiol ingangcoliswa nezinye izithako ezingaba yingozi kumntwana noma usana. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Izingane: Umkhiqizo kadokotela we-cannabidiol (i-Epidiolex) ngu OKUNGENZEKA UKUPHEPHA lapho ithathwa ngomlomo ngemithamo efinyelela ku-25 mg / kg nsuku zonke. Lo mkhiqizo uvunyelwe ukusetshenziswa ezinganeni ezithile ezinonyaka owodwa nangaphezulu.

Isifo sesibindi: Abantu abanesifo sesibindi bangadinga ukusebenzisa imithamo ephansi ye-cannabidiol uma kuqhathaniswa neziguli ezinempilo.

Isifo se-Parkinson: Olunye ucwaningo lwakuqala lukhombisa ukuthi ukuthatha imithamo ephezulu ye-cannabidiol kungenza ukunyakaza kwemisipha nokuzamazama kube kubi kakhulu kubantu abanesifo i-Parkinson.

Maphakathi
Qaphela ngale nhlanganisela.
I-Brivaracetam (Briviact)
I-Brivaracetam iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani i-brivaracetam ngokushesha. Lokhu kungakhuphula amazinga we-brivaracetam emzimbeni.
I-Carbamazepine (Tegretol)
ICarbamazepine iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani ngokushesha i-carbamazepine. Lokhu kungakhuphula amazinga e-carbamazepine emzimbeni futhi kukhulise imiphumela yawo emibi.
I-Clobazam (Onfi)
I-Clobazam iyashintshwa futhi yephulwe yisibindi. I-Cannabidiol inganciphisa ukuthi isibindi sidiliza kanjani i-clobazam ngokushesha. Lokhu kungakhuphula imiphumela kanye nemiphumela emibi ye-clobazam.
I-Eslicarbazepine (Aptiom)
I-Eslicarbazepine iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol ingahle yehle ukuthi umzimba wehla ngokushesha kangakanani i-eslicarbazepine. Lokhu kungakhuphula amazinga e-eslicarbazepine emzimbeni ngenani elincane.
I-Everolimus (iZostress)
I-Everolimus iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wehla kanjani ngokushesha i-everolimus. Lokhu kungakhuphula amazinga e-everolimus emzimbeni.
ILithium
Ukuthatha imithamo ephakeme ye-cannabidiol kungakhuphula amazinga e-lithium. Lokhu kungakhuphula ubungozi be-lithium toxicity.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 1A1 (CYP1A1))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imithi eshintshwe yisibindi ifaka i-chlorzoxazone (i-Lorzone) ne-theophylline (Theo-Dur, eminye).
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 1A2 (CYP1A2))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eshintshwe yisibindi ihlanganisa i-amitriptyline (Elavil), i-haloperidol (i-Haldol), i-ondansetron (i-Zofran), i-propranolol (i-Inderal), i-theophylline (i-Theo-Dur, abanye), i-verapamil (i-Calan, i-Isoptin, abanye), neminye.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 1B1 (CYP1B1))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imithi eshintshwe yisibindi ifaka i-theophylline (Theo-Dur, eminye), i-omeprazole (Prilosec, i-Omesec), i-clozapine (i-Clozaril, i-FazaClo), i-progesterone (i-Prometrium, abanye), i-lansoprazole (i-Prevacid), i-flutamide (i-Eulexin), i-oxaliplatin (i-Eloxatin) ), i-erlotinib (iTarceva), ne-caffeine.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2A6 (CYP2A6))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eshintshwe yisibindi ifaka i-nicotine, i-chlormethiazole (i-Heminevrin), i-coumarin, i-methoxyflurane (i-Penthrox), i-halothane (i-Fluothane), i-valproic acid (i-Depacon), i-disulfiram (i-Antabuse), neminye.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2B6 (CYP2B6))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imithi eshintshwe yisibindi ifaka phakathi i-ketamine (Ketalar), i-phenobarbital, i-orphenadrine (i-Norflex), i-secobarbital (i-Seconal), ne-dexamethasone (i-Decadron).
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2C19 (CYP2C19))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eguqulwe isibindi ifaka phakathi ama-proton pump inhibitors afaka i-omeprazole (Prilosec), i-lansoprazole (i-Prevacid), ne-pantoprazole (i-Protonix); diazepam (Valium); i-carisoprodol (iSoma); i-nelfinavir (i-Viracept); nabanye.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2C8 (CYP2C8))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.
Eminye imithi eshintshwe yisibindi ihlanganisa i-amiodarone (Cordarone), i-carbamazepine (Tegretol), i-chloroquine (i-Aralen), i-diclofenac (i-Voltaren), i-paclitaxel (i-Taxol), i-repaglinide (i-Prandin) neminye.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2C9 (CYP2C9))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sehla ngokushesha kanjani eminye imithi. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eguqulwe isibindi ifaka izidakamizwa ezingezona ukuvuvukala (ama-NSAID) ezinjenge-diclofenac (Cataflam, Voltaren), ibuprofen (Motrin), meloxicam (Mobic), piroxicam (Feldene), ne-celecoxib (Celebrex); i-amitriptyline (u-Elavil); i-warfarin (i-Coumadin); i-glipizide (iGlucotrol); losartan (Cozaar); nabanye.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 2D6 (CYP2D6))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol inganciphisa ukuthi isibindi siqeda kanjani imithi ethile ngokushesha. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eguqulwe isibindi ifaka i-amitriptyline (Elavil), i-codeine, i-desipramine (i-Norpramin), i-flecainide (i-Tambocor), i-haloperidol (i-Haldol), i-imipramine (i-Tofranil), i-metoprolol (i-Lopressor, i-Toprol XL), i-ondansetron (i-Zofran), i-paroxetine (i-Paxiletine) ), risperidone (Risperdal), tramadol (Ultram), venlafaxine (Effexor), nabanye.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 3A4 (CYP3A4))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol inganciphisa ukuthi isibindi siqeda kanjani imithi ethile ngokushesha. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imithi eshintshwe yisibindi ihlanganisa i-alprazolam (Xanax), i-amlodipine (i-Norvasc), i-clarithromycin (i-Biaxin), i-cyclosporine (iSandimmune), i-erythromycin, i-lovastatin (i-Mevacor), i-ketoconazole (i-Nizoral), i-itraconazole (i-Sporanox), i-fexofenadine (Halcion), verapamil (Calan, Isoptin) nabanye abaningi.
Imithi ishintshwe yisibindi (iziqhekeza zeCytochrome P450 3A5 (CYP3A5))
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol inganciphisa ukuthi isibindi siqeda kanjani imithi ethile ngokushesha. Ngokwethiyori, ukusebenzisa i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yeminye imithi. Ngaphambi kokusebenzisa i-cannabidiol, khuluma nomhlinzeki wakho wezokunakekelwa kwezempilo uma uthatha noma yimiphi imithi eshintshwa yisibindi.

Eminye imishanguzo eshintshwe yisibindi ifaka phakathi i-testosterone, progesterone (Endometrin, Prometrium), nifedipine (Adalat CC, Procardia XL), cyclosporine (Sandimmune), neminye.
Imithi eshintshwe yisibindi (Izidakamizwa ezinesibindi)
Eminye imishanguzo iyashintshwa futhi yephulwe isibindi. I-Cannabidiol inganciphisa ukuthi isibindi siqeda kanjani imithi ethile ngokushesha. Ukuthatha i-cannabidiol kanye neminye imithi eyehliswe yisibindi kungakhuphula imiphumela kanye nemiphumela emibi yale mithi.
Eminye yale mithi eshintshwe yisibindi ihlanganisa i-acetaminophen (iTylenol, eminye) ne-oxazepam (Serax), haloperidol (Haldol), lamotrigine (Lamictal), morphine (MS Contin, Roxanol), zidovudine (AZT, Retrovir), neminye.
Imithi eyehlisa ukuwohloka kweminye imithi ngesibindi (Cytochrome P450 2C19 (CYP2C19) inhibitors)
I-Cannabidiol idilizwe yisibindi. Eminye imishanguzo inganciphisa ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol. Ukuthatha i-cannabidiol kanye nale mithi kungakhuphula imiphumela kanye nemiphumela emibi ye-cannabidiol.
Eminye imishanguzo enganciphisa ukonakala kwe-cannabidiol esibindini ifaka i-cimetidine (Tagamet), i-fluvoxamine (i-Luvox), i-omeprazole (i-Prilosec); ticlopidine (Ticlid), topiramate (Topamax), nabanye.
Imithi eyehlisa ukuwohloka kweminye imithi esibindini (i-Cytochrome P450 3A4 (CYP3A4) inhibitors)
I-Cannabidiol idilizwe yisibindi. Eminye imishanguzo inganciphisa ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol. Ukuthatha i-cannabidiol kanye nale mithi kungakhuphula imiphumela kanye nemiphumela emibi ye-cannabidiol.
Eminye imishanguzo enganciphisa ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol ifaka i-amiodarone (Cordarone), i-clarithromycin (i-Biaxin), i-diltiazem (i-Cardizem), i-erythromycin (i-E-mycin, i-Erythrocin), i-indinavir (i-Crixivan), i-ritonavir (i-Norvir), i-saquinavir (i-Fortovase) , Invirase), nabanye abaningi.
Imithi ekhulisa ukuwohloka kweminye imithi ngesibindi (i-Cytochrome P450 3A4 (CYP3A4) inducers)
I-Cannabidiol idilizwe yisibindi. Eminye imishanguzo ingakhuphula ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol. Ukuthatha i-cannabidiol kanye nale mithi kunganciphisa imiphumela ye-cannabidiol.
Eminye yale mithi ifaka i-carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), neminye.
Imithi ekhulisa ukuwohloka kweminye imithi ngesibindi (i-Cytochrome P450 2C19 (CYP2C19) inducers)
I-Cannabidiol idilizwe yisibindi. Eminye imishanguzo ingakhuphula ukuthi isibindi sehla ngokushesha kanjani i-cannabidiol. Ukuthatha i-cannabidiol kanye nale mithi kunganciphisa imiphumela ye-cannabidiol.
Eminye imithi engakhuphula ukuwohloka kwe-cannabidiol esibindini ifaka i-carbamazepine (Tegretol), i-prednisone (i-Deltasone), ne-rifampin (i-Rifadin, i-Rimactane).
I-Methadone (Dolophine)
IMethadone idilizwe yisibindi. I-Cannabidiol ingahle yehlise ukuthi isibindi sidiliza kanjani i-methadone ngokushesha. Ukuthatha i-cannabidiol kanye ne-methadone kungakhuphula imiphumela kanye nemiphumela emibi ye-methadone.
I-Rufinamide (Banzel)
URufinamide uyashintshwa futhi wephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani i-rufinamide ngokushesha okukhulu. Lokhu kungakhuphula amazinga e-rufinamide emzimbeni ngenani elincane.
Imithi yokudambisa (i-CNS depressants)
I-Cannabidiol ingadala ubuthongo nokulala. Imithi ebanga ubuthongo ibizwa ngokuthi yimithi yokuthambisa. Ukuthatha i-cannabidiol kanye nemithi yokwelapha kungadala ukulala kakhulu.

Eminye imishanguzo yokuthambisa ibandakanya i-benzodiazepines, i-pentobarbital (i-Nembutal), i-phenobarbital (i-Luminal), i-secobarbital (i-Seconal), i-thiopental (i-Pentothal), i-fentanyl (i-Duragesic, i-Sublimaze), i-morphine, i-propofol (i-Diprivan), neminye.
I-Sirolimus (Rapamune)
I-Sirolimus iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wehla ngokushesha kanjani i-sirolimus. Lokhu kungakhuphula amazinga e-sirolimus emzimbeni.
I-Stiripentol (Diacomit)
I-Stiripentol iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula ngokushesha kanjani i-stiripentol. Lokhu kungakhuphula amazinga e-stiripentol emzimbeni futhi kwandise imiphumela yawo emibi.
I-Tacrolimus (Prograf)
I-tacrolimus iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba weqa kanjani ngokushesha i-tacrolimus. Lokhu kungakhuphula amazinga we-tacrolimus emzimbeni.
I-Topiramate (Tompamax)
I-Topiramate ishintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani ngokushesha i-topiramate. Lokhu kungakhuphula amazinga we-topiramate emzimbeni ngenani elincane.
I-Valproate
I-Valproic acid ingadala ukulimala kwesibindi. Ukuthatha i-cannabidiol nge-valproic acid kungandisa amathuba okulimala kwesibindi. I-Cannabidiol kanye / noma i-valproic acid ingadinga ukumiswa, noma umthamo ungadinga ukwehliswa.
I-Warfarin
I-Cannabidiol ingakhuphula amazinga e-warfarin, angakhuphula ingozi yokuphuma kwegazi. I-Cannabidiol kanye / noma i-warfarin ingadinga ukumiswa, noma umthamo ungadinga ukwehliswa.
Zonisamide
I-Zonisamide iyashintshwa futhi yephulwe ngumzimba. I-Cannabidiol inganciphisa ukuthi umzimba wephula kanjani ngokushesha i-zonisamide. Lokhu kungakhuphula amazinga we-zonisamide emzimbeni ngenani elincane.
Amakhambi kanye nezithasiselo ezinezakhiwo zokuthambisa
I-Cannabidiol ingadala ukulala noma ukozela. Ukuyisebenzisa kanye namanye amakhambi nezithako ezinomphumela ofanayo kungadala ukulala okuningi. Amanye alawa makhambi nezithasiselo afaka i-calamus, i-poppy yaseCalifornia, i-catnip, i-hops, i-dogwood yaseJamaican, i-kava, i-L-tryptophan, i-melatonin, i-sage, i-SAMe, i-wort yaseSt.
Utshwala (i-Ethanol)
Ukuthatha i-cannabidiol ngotshwala kwandisa inani le-cannabidiol elimuncwa umzimba. Lokhu kungakhuphula imiphumela nemiphumela emibi ye-cannabidiol.
Amafutha nokudla okuqukethe amafutha
Ukuthatha i-cannabidiol ngesidlo esinamafutha amaningi noma okungenani kuqukethe amafutha, kwandisa inani le-cannabidiol elimuncwa umzimba. Lokhu kungakhuphula imiphumela nemiphumela emibi ye-cannabidiol.
Ubisi
Ukuthatha i-cannabidiol ngobisi kwandisa inani le-cannabidiol elimuncwa umzimba. Lokhu kungakhuphula imiphumela emibi ye-cannabidiol.
Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:
  • Isifo sokuwa: Kusetshenziswe umkhiqizo kadokotela we-cannabidiol (i-Epidiolex). Umthamo onconywayo wokuqala weLennox-Gastaut syndrome ne-Dravet syndrome ngu-2.5 mg / kg kabili ngosuku (5 mg / kg / ngosuku). Ngemuva kwesonto elilodwa umthamo ungakhuphukela ku-5 mg / kg kabili ngosuku (10 mg / kg / ngosuku). Uma umuntu engaphenduli kulo mthamo, isilinganiso esiphakanyisiwe ngu-10 mg / kg kabili ngosuku (20 mg / kg / ngosuku). Umthamo onconywayo wokuqala we-tuberous sclerosis complex ngu-2.5 mg / kg kabili ngosuku (5 mg / kg / ngosuku). Lokhu kungakhuphuka ngezikhathi zamasonto onke uma kunesidingo, kuze kufike ku-12.5 mg / kg kabili ngosuku (25 mg / kg / ngosuku). Abukho ubufakazi obuqinile besayensi bokuthi imikhiqizo ye-cannabidiol engabhalisiwe iyazuzisa ngesifo sokuwa.
IZINGANE

NGOMLOMO:
  • Isifo sokuwa: Kusetshenziswe umkhiqizo kadokotela we-cannabidiol (i-Epidiolex). Umthamo onconywayo wokuqala weLennox-Gastaut syndrome ne-Dravet syndrome ngu-2.5 mg / kg kabili ngosuku (5 mg / kg / ngosuku). Ngemuva kwesonto elilodwa umthamo ungakhuphukela ku-5 mg / kg kabili ngosuku (10 mg / kg / ngosuku). Uma umuntu engaphenduli kulo mthamo, ubukhulu obuphakanyisiwe ngu-10 mg / kg kabili ngosuku (20 mg / kg / ngosuku). Umthamo onconywayo wokuqala we-tuberous sclerosis complex ngu-2.5 mg / kg kabili ngosuku (5 mg / kg / ngosuku). Lokhu kungakhuphuka ngezikhathi zamasonto onke uma kunesidingo, kuze kufike ku-12.5 mg / kg kabili ngosuku (25 mg / kg / ngosuku). Abukho ubufakazi obuqinile besayensi bokuthi imikhiqizo ye-cannabidiol engabhalisiwe iyazuzisa ngesifo sokuwa.
2 - [(1R, 6R) -3-Methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl] -5-pentylbenzene-1,3-diol, CBD.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.


  1. USingh RK, uDillon B, uTatum DA, uVan Poppel KC, uBonthius DJ. Ukusebenzisana Kwezidakamizwa Nezidakamizwa Phakathi KweCannabidiol neLithium. Ingane Neurol Ivulekile. 2020; 7: 2329048X20947896. Buka okungaqondakali.
  2. Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic uphenyo lokwenziwa kwe-cannabidiol ukwenziwa ngomlomo kumavolontiya anempilo. I-Eur J Pharm Biopharm. 2020; 154: 108-115. Buka okungaqondakali.
  3. UGurley BJ, uMurphy TP, uGul W, uWalker LA, u-ElSohly M. Okuqukethwe kuqhathaniswa nezimangalo zelebula eCannabidiol (CBD) -Iqukethe Imikhiqizo Etholakale Ezitolo Zezentengiselwano eSifundazweni SaseMississippi. J Ukudla Suppl. 2020; 17: 599-607. Buka okungaqondakali.
  4. UMcGuire P, uRobson P, uCubala WJ, et al. I-Cannabidiol (i-CBD) njenge-Adjunctive Therapy eSchizophrenia: Isivivinyo Esilawulwa Ngokungahleliwe Esilawulwa Ngezikhathi Eziningi. Am J Psychiatry. 2018; 175: 225-231. Buka okungaqondakali.
  5. Ukulungiswa komthamo weCortopassi J. Warfarin kuyadingeka ngemuva kokuqala kwe-cannabidiol kanye ne-titration. NginguJ J Health Syst Pharm. 2020; 77: 1846-1851. Buka okungaqondakali.
  6. IBloomfield MAP, iGreen SF, uHindocha C, et al. Imiphumela ye-cannabidiol ebukhali ekugelezeni kwegazi lobuchopho nobudlelwano bayo nenkumbulo: Ucwaningo lwe-arterial spin lokufaka uphawu lokucabanga ngemagnificent resonance. J I-Psychopharmacol. 2020; 34: 981-989. Buka okungaqondakali.
  7. UWang GS, uBourne DWA, uKlawitter J, et al. Ukuchithwa kwe-Oral Cannabidiol-Rich Cannabis Extracts ezinganeni ezine-Epilepsy. Umtholampilo Pharmacokinet. 2020. Buka okungaqondakali.
  8. UTaylor L, Crockett J, Tayo B, uChecketts D, uSommerville K. Ukuhoxiswa okungazelelwe kwe-cannabidiol (CBD): Isivivinyo esingahleliwe. Isifo sokuwa Behav. 2020; 104 (Pt A): 106938. Buka okungaqondakali.
  9. UMcNamara NA, uDang LT, uStrurza J, et al. I-Thrombocytopenia ezigulini zezingane ku-cannabidiol kanye ne-valproic acid efanayo. Isifo sokuwa. 2020. Buka okungaqondakali.
  10. URianprakaisang T, uGerona R, uHendrickson RG. Uwoyela wezohwebo we-cannabidiol ungcoliswe ne-synthetic cannabinoid AB-FUBINACA enikezwe isiguli sezingane. IClin Toxicol (Phila). 2020; 58: 215-216. Buka okungaqondakali.
  11. UMorrison G, Crockett J, Blakey G, Sommerville K. Isigaba 1, i-Open-Label, Isivivinyo se-Pharmacokinetic Sokuphenya Ukusebenzisana Okungenzeka Ngezidakamizwa Phakathi Kwezinhlayiya zeClobazam, iStiripentol, noma iValproate neCannabidiol ezifundweni ezinempilo. I-Clin Pharmacol Izidakamizwa. 2019; 8: 1009-1031. Buka okungaqondakali.
  12. UMiller I, uScheffer IE, uGunning B, et al. Umphumela Oguqula Umthamo we-Adjunctive Oral Cannabidiol vs Placebo ku-Convulsive Seizure Frequency e-Dravet Syndrome: Isivivinyo Somtholampilo Esingahleliwe. I-JAMA Neurol. 2020; 77: 613-621. Buka okungaqondakali.
  13. ILattanzi S, Trinka E, Striano P, et al. Ukusebenza kwe-Cannabidiol nesimo se-clobazam: Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. Isifo sokuwa. 2020; 61: 1090-1098. Buka okungaqondakali.
  14. IHobbs JM, iVazquez AR, iRemijan ND, et al. Ukuhlolwa kwe-pharmacokinetics kanye namandla amakhulu okulwa nokuvuvukala kwamalungiselelo amabili we-oral cannabidiol kubantu abadala abaphilile. I-Phytother Res. 2020; 34: 1696-1703. Buka okungaqondakali.
  15. U-Ebrahimi-Fakhari D, u-Agricola KD, uTudor C, uKrueger D, uFranz DN. I-Cannabidiol Iphakamisa Ukuqondiswa Kwemishini Yezinga Le-Rapamycin Inhibitor Ezigulini Ezine-Tuberous Sclerosis Complex. I-Pediatr Neurol. 2020; 105: 59-61. Buka okungaqondakali.
  16. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Ukusebenza kanye nomlando omubi we-cannabidiol ne-cannabis yokwelapha yesifo sokuwa esingazweli ekwelashweni: Ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta. Isifo sokuwa Behav. 2020; 102: 106635. Buka okungaqondakali.
  17. I-Darweesh RS, i-Khamis TN, i-El-Elimat T. Umphumela we-cannabidiol ku-pharmacokinetics ye-carbamazepine kumagundane. UNaunyn Schmiedebergs Arch Pharmacol. 2020. Buka okungaqondakali.
  18. ICrockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. Isigaba 1, ukuhlolwa okungahleliwe, kwe-pharmacokinetic komphumela wezingoma ezahlukahlukene zokudla, ubisi lonke, notshwala ekuvezweni kwe-cannabidiol nokuphepha ezifundweni ezinempilo. Isifo sokuwa. 2020; 61: 267-277. Buka okungaqondakali.
  19. UChesney E, u-Oliver D, uGreen A, et al. Imiphumela emibi ye-cannabidiol: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kokuhlolwa komtholampilo okungahleliwe. I-Neuropsychopharmacology. 2020. Buka okungaqondakali.
  20. UBen-Menachem E, uGunning B, u-Arenas Cabrera CM, et al. Isivivinyo Esingahleliwe Sesigaba II Ukuhlola Okungenzeka Kokuhlangana Kwemithi Yezidakamizwa Nezidakamizwa ne-Stiripentol noma iValproate lapho kuhlanganiswe neCannabidiol ezigulini ezinesifo sokuwa. Izidakamizwa ze-CNS. 2020; 34: 661-672. Buka okungaqondakali.
  21. UBass J, uLinz DR. Icala Lobuthi kusuka ku-Cannabidiol Gummy Ingestion. UCureus. 2020; 12: e7688. Buka okungaqondakali.
  22. I-Hampson AJ, i-Grimaldi M, i-Axelrod J, i-Wink D. I-Cannabidiol kanye (-) ne-Delta9-tetrahydrocannabinol yi-antioxidants ye-neuroprotective. I-Proc Natl Acad Sci U S A. 1998; 95: 8268-73. Buka okungaqondakali.
  23. IHacke ACM, uLima D, de Costa F, et al. Ukuhlola umsebenzi we-antioxidant we [delta] -tetrahydrocannabinol ne-cannabidiol kwizicashunwa zeCannabis sativa. Umhlaziyi. 2019; 144: 4952-4961. Buka okungaqondakali.
  24. UMadden K, uTanco K, uBruera E. Ukusebenzisana Okubalulekile Kwezidakamizwa Nezidakamizwa Phakathi Kwemethadone neCannabidiol. Izifo zezingane. 2020; e20193256. Buka okungaqondakali.
  25. IHazekamp A. Inkinga ngamafutha e-CBD. I-Med Cannabis Cannabinoids. 2018 Jun; 1: 65-72.
  26. I-Xu DH, i-Cullen BD, i-Tang M, i-Fang Y. Ukusebenza kwe-Topical Cannabidiol Oil ku-Sympomatic Relief ye-Peripheral Neuropathy ye-Lower Extremities. ICurr Pharm Biotechnol. 2019 Dis 1. Buka okungaqondakali.
  27. de Faria SM, de Morais Fabrício D, Tumas V, et al. Imiphumela yokuphathwa okunamandla kwe-cannabidiol ekukhathazekeni nasekuthuthumeleni okubangelwa yi-Simulated Public Speaking Test ezigulini ezinesifo sikaParkinson. J I-Psychopharmacol. 2020 uJan 7: 269881119895536. Buka okungaqondakali.
  28. UNitecka-Buchta A, uNowak-Wachol A, uWachol K, et al. Umphumela we-Myorelaxant we-Transdermal Cannabidiol Application ezigulini ezine-TMD: Isivivinyo Esingahleliwe, Esiphofu kabili. UJ Clin Med. 2019 uNov 6; 8. pii: E1886. Buka okungaqondakali.
  29. IMasataka N. Imiphumela ye-Anxiolytic Yokwelapha Okuphindaphindiwe Kwe-Cannabidiol Kwentsha Enenkinga Yokukhathazeka Komphakathi. Ingqondo yangaphambili. 2019 Novemba 8; 10: 2466. Buka okungaqondakali.
  30. U-Appiah-Kusi E, Petros N, Wilson R, et al. Imiphumela yokwelashwa kwesikhashana kwe-cannabidiol ekuphenduleni ekucindezelekeni komphakathi ezifundweni ezisengozini enkulu yomtholampilo yokuthola isifo sengqondo. I-Psychopharmacology (i-Berl). 2020 Jan 8. Buka okungaqondakali.
  31. UHussain SA, uDlugos DJ, uCilio MR, Parikh N, Oh A, Sankar R. Synthetic pharmaceutical grade cannabidiol ekwelapheni ama-spasms wezinsana aphikisayo: Isifundo se-multicenter phase-2. Isifo sokuwa Behav. 2020 uJan; 102: 106826. Buka okungaqondakali.
  32. UKlotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Ukusebenza nokubekezelela kwe-Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy. Ngaphambili Neurol. 2019 Disemba 10; 10: 1313. Buka okungaqondakali.
  33. "IGW Pharmaceuticals plc kanye ne-Its U.S. Subsidiary Greenwich Biosciences, Inc. Imemezela Ukuthi Isixazululo Somlomo Se-EPIDIOLEX® (cannabidiol) Sihlelelwe Isikhathi Futhi Akuseyona Into Elawulwayo." I-GW Pharmaceuticals, 6 Ephreli 2020. http://ir.gwpharm.com/node/11356/pdf. Isitatimende sephephandaba.
  34. UWiemer-Kruel A, uStiller B, uBast T. Cannabidiol Uxhumana Ngokuphawulekayo ne-Everolimus-Umbiko Wesiguli EsineTuberous Sclerosis Complex. Neuropediatrics. 2019. Buka okungaqondakali.
  35. Ukubuyekezwa Kwabathengi be-FDA: Okufanele Ukwazi Ngokusebenzisa Insangu, Kubandakanya i-CBD, Lapho Ukhulelwe noma Uncelisa. U. S. Food and Drug Administration (FDA). Okthoba 2019. Kutholakala ku: https://www.fda.gov/consumers/consumer-updates/what-you-should-now-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.
  36. UTaylor L, Crockett J, Tayo B, Morrison G. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. UJ Clin Pharmacol. 2019; 59: 1110-1119. Buka okungaqondakali.
  37. USzaflarski JP, uHernando K, uBebin EM, et al. Izinga eliphakeme le-plasma le-cannabidiol lihlotshaniswa nempendulo yokubanjwa ngcono kokulandela ukwelashwa ngebanga lemithi i-cannabidiol. Isifo sokuwa Behav. 2019; 95: 131-136. Buka okungaqondakali.
  38. UPretzsch CM, uVoinescu B, uMendez MA, et al. Umphumela we-cannabidiol (i-CBD) ekusebenzeni kwemvamisa ephansi nasekuxhumaneni okusebenzayo ebuchosheni babantu abadala abane-Autism spectrum disorder (ASD) nangaphandle kwayo. J I-Psychopharmacol. 2019: 269881119858306. Buka okungaqondakali.
  39. UPretzsch CM, uFreyberg J, uVoinescu B, et al. Imiphumela ye-cannabidiol ekujabuliseni ubuchopho nezinhlelo zokuvimbela; isilingo sedosi esisodwa esilawulwa ngokungahleliwe ngesikhathi sokubukwa kwesibonisi samagnetic kubantu abadala abane-disorder ye-autism nangaphandle kwayo. I-Neuropsychopharmacology. 2019; 44: 1398-1405. Buka okungaqondakali.
  40. UPatrician A, uVeric-Bratincevic M, uMijacika T, et al. Ukuhlolwa kwendlela entsha yokulethwa kwe-Oral Cannabidiol ezifundweni ezinempilo: Isifundo se-Pharmacokinetics Study esenziwe ngokungahleliwe, esimpumputhe kabili. U-Adv Ther. 2019. Buka okungaqondakali.
  41. UMartin RC, uGaston TE, uThompson M, et al. Ukusebenza kwengqondo kulandela ukusetshenziswa kwesikhathi eside kwe-cannabidiol kubantu abadala abanesithuthwane esingazweli ekwelashweni. Isifo sokuwa Behav. 2019; 97: 105-110. Buka okungaqondakali.
  42. Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Ubufakazi bokusebenzisana okuphawulekayo kwezidakamizwa phakathi kwezidakamizwa ne-tacrolimus. NginguJ J ukufakelwa kabusha. 2019; 19: 2944-2948. Buka okungaqondakali.
  43. I-Laux LC, i-Bebin EM, i-Checketts D, et al. Ukuphepha kwesikhathi eside nokusebenza kwe-cannabidiol ezinganeni nakubantu abadala abane-Lennox-Gastaut syndrome noma i-Dravet syndrome emelana nokwelashwa: Imiphumela yohlelo lokufinyelela olwandisiwe. Isithuthwane Res. 2019; 154: 13-20. Buka okungaqondakali.
  44. UKnaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Ngokuya nge-VESIsorb Formulation Technology Ukuthuthukisa ukutholakala komlomo kweCannabidiol ezifundweni ezinempilo. Ama-molecule. 2019; 24. i-pii: E2967. Buka okungaqondakali.
  45. UKlotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Imiphumela ye-cannabidiol kumazinga we-brivaracetam plasma. Isifo sokuwa. 2019; 60: e74-e77. Buka okungaqondakali.
  46. UHeussler H, uCohen J, uSilove N, et al. Isigaba i-1/2, ukuhlolwa kwelebula evulekile kokuphepha, ukubekezelela, nokusebenza kwe-transdermal cannabidiol (ZYN002) ekwelapheni isifo esibuthakathaka se-X syndrome. J Neurodev Ukungezwani. 2019; 11: 16. Buka okungaqondakali.
  47. Umbhede DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE. I-Palmitoylethanolamide ne-Cannabidiol Vimbela i-Hyperpermeability ebangelwa ukuvuvukala kwe-Human Gut In Vitro ne-In Vivo-A Randomised, Placebo-controlled, Double-blind Trial Trial. I-Inflamm Bowel Dis. 2019; 25: 1006-1018. Buka okungaqondakali.
  48. UBirnbaum AK, uKaranam A, uMarino SE, et al. Umphumela wokudla kuma-pharmacokinetics we-cannabidiol amaphilisi omlomo ezigulini zabantu abadala abanesithuthwane esiphikisayo. Isifo sokuwa. 2019 Aug; 60: 1586-1592. Buka okungaqondakali.
  49. U-Arkell TR, uLintzeris N, uKevin RC, et al. Okuqukethwe kwe-Cannabidiol (CBD) ku-cannabis ephefumulelwe akuvimbeli ukukhubazeka kwe-tetrahydrocannabinol (THC) okuthinta ukushayela nokuqonda. I-Psychopharmacology (i-Berl). 2019; 236: 2713-2724. Buka okungaqondakali.
  50. U-Anderson LL, u-Absalom NL, u-Abelev SV, et al. I-cannabidiol ephethwe yi-Coadministered kanye ne-clobazam: Ubufakazi bokutholwa kokusebenzisana kwe-pharmacodynamic kanye ne-pharmacokinetic. Isifo sokuwa. 2019. Buka okungaqondakali.
  51. Imininingwane yomkhiqizo weMarinol. AbbVie. ENyakatho Chicago, IL 60064. Agasti 2017.Kutholakala ku: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
  52. I-Epidiolex (cannabidiol) enquma imininingwane. IGreenwich Biosciences, Inc., iCarlsbad, CA, 2019. Itholakala ku: https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf (kufinyelelwe ngomhla ka-5/9/2019)
  53. Isitatimende esivela kuKhomishani we-FDA uScot Gottlieb, MD, ngokusayinwa koMthetho Wokuthuthukiswa Kwezolimo kanye nokulawulwa kwe-ejensi yemikhiqizo equkethe i-cannabis kanye nezakhi ezitholakala nge-cannabis. Iwebhusayithi ye-U.S.U. Kutholakala ku: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Kufinyelelwe ngoMeyi 7, 2019).
  54. Umthetho Wezokuthuthukiswa Kwezolimo, S. 10113, 115th Cong. noma S. 12619, 115th Cong. .
  55. Ukuphathwa Kwezokuphathwa Kwezidakamizwa, uMnyango Wezobulungiswa. Amashejuli Ezinto Ezilawulwayo: Ukubekwa Kusheduli V Yezidakamizwa Ezithile Ezamukelwe yi-FDA Eziqukethe I-Cannabidiol; Ushintsho Oluhambelana Nezimfuneko Zemvume. I-oda lokugcina. Ukubhaliswa Kwezezimali. 2018 Sep 28; 83: 48950-3. Buka okungaqondakali.
  56. ISchoedel KA, Szeto I, Setnik B, et al. Ukuhlolwa okungahle kube khona kokuhlukunyezwa kwe-cannabidiol (i-CBD) kubasebenzisi bokuzithokozisa be-polydrug: Isivivinyo esilawulwa ngokungahleliwe, esiyimpumputhe, nesilawulwa. Isifo sokuwa Behav. 2018 Nov; 88: 162-171. i-doi: 10.1016 / j.yebeh.2018.07.027. I-Epub 2018 Oct 2. Buka okungaqondakali.
  57. UDevinsky O, Verducci C, Thiele EA, et al. Ukusetshenziswa kwelebula evulekile kwe-CBD ehlanzwe kakhulu (i-Epidiolex®) ezigulini ezinesifo sokushoda kwe-CDKL5 kanye ne-Aicardi, Dup15q, neDoose syndromes. Isifo sokuwa Behav. 2018 Septhemba; 86: 131-137. I-Epub 2018 Jul 11. Buka okungaqondakali.
  58. USzaflarski JP, uBebin EM, umsiki G, uDeWolfe J, et al. I-Cannabidiol ithuthukisa imvamisa nobukhali bokuquleka futhi inciphisa izehlakalo ezimbi kusifundo esizoba khona selebuli evulekile. Isifo sokuwa Behav. 2018 Okthoba; 87: 131-136. I-Epub 2018 Aug 9. Buka okungaqondakali.
  59. ILinares IM, iZuardi AW, iPereira LC, et al. I-Cannabidiol iveza ijika lempendulo ye-U elime ngendlela evunyiwe ekuhlolweni kokukhuluma komphakathi. UBraz J Psychiatry. 2019 UJan-Feb; 41: 9-14. I-Epub 2018 Oct 11. Buka okungaqondakali.
  60. I-Poklis JL, Mulder HA, Ukuthula MR. Ukukhonjwa okungalindelekile kwe-cannabimimetic, 5F-ADB, ne-dextromethorphan kuma-cannabidiol e-liquids athengiswayo. I-Forensic Sci Int. 2019 uJan; 294: e25-e27. I-Epub 2018 Nov 1. Buka okungaqondakali.
  61. Kulimaze i-YL, i-Spriggs S, i-Alishayev J, et al. I-Cannabidiol Yokwehliswa Kwesifiso Esenziwe Nge-Cue-Ukukhathazeka Nabantu Abangavumeli Izidakamizwa Abantu Abane-Disorder Use Disorder: Isivivinyo Esilawulwa Nge-Placebo Esilawulwa Kabili. NginguJ J Psychiatry. 2019: uhlelo lokusebenza201918101191. Buka okungaqondakali.
  62. UThiele EA, Marsh ED, French JA, et al. I-Cannabidiol ezigulini ezinokuquleka okuhambisana ne-Lennox-Gastaut syndrome (GWPCARE4): isilingo esilawulwa nge-placebo esilawulwa ngokungahleliwe, esimpumputhe kabili. I-Lancet. 2018 uMar 17; 391: 1085-1096. Buka okungaqondakali.
  63. UDevinsky O, uPatel AD, uCross JH, et al. Umphumela weCannabidiol Ekuqubuzeni Kokwehla kuLennox-Gastaut Syndrome. N Engl J Med. 2018 Meyi 17; 378: 1888-1897. Buka okungaqondakali.
  64. UPavlovic R, uNenna G, uCalvi L, et al. Izici Zekhwalithi ze "Amafutha e-Cannabidiol": Okuqukethwe kwe-Cannabinoids, i-Terpene Fingerprint kanye ne-Oxidation Stability of European Commercially Preparations. Ama-molecule. 2018 uMeyi 20; 23. pii: E1230. Buka okungaqondakali.
  65. UJannasch F, uKröger J, uSchulze MB. Amaphethini Okudla kanye nohlobo 2 Lwesifo Sikashukela: Ukubuyekezwa Kwezincwadi Ezihlelekile kanye Nokuhlaziywa Kwemeta Yezifundo Ezizokwenzeka. J Umsoco. 2017 Juni; 147: 1174-1182. Buka okungaqondakali.
  66. UNaftali T, Mechulam R, Marii A, et al. Umthamo ophansi we-cannabidiol uphephile kepha awusebenzi ekwelapheni iSifo sikaCrohn, isilingo esilawulwa ngokungahleliwe. I-Dig Dis Sci. 2017 uJuni; 62: 1615-20. Buka okungaqondakali.
  67. IKaplan EH, i-Offermann EA, iSievers JW, iComi AM. Ukwelashwa kwe-Cannabidiol ngokuhlaselwa okukhanyelayo ku-Sturge-Weber Syndrome. I-Pediatr Neurol. 2017 Juni; 71: 18-23.e2. Buka okungaqondakali.
  68. U-Yeshurun ​​M, uShippilberg O, uHerscovici C, et al. I-Cannabidiol yokuvimbela isifo se-graft-versus-host-disease ngemuva kokufakelwa kabusha kwe-allogeneic hematopoietic cell: imiphumela yocwaningo lwesigaba II. Ukufakelwa kabusha kwe-Biol Blood Marrow. 2015 Okthoba; 21: 1770-5. Buka okungaqondakali.
  69. UGeffrey AL, uPollack SF, uBruno PL, uThiele EA. Ukusebenzisana kwezidakamizwa nezidakamizwa phakathi kwe-clobazam ne-cannabidiol ezinganeni ezinesithuthwane esiphikisayo. Isifo sokuwa. 2015 Aug; 56: 1246-51. Buka okungaqondakali.
  70. UDevinsky O, uMarsh E, uFriedman D, et la. I-Cannabidiol ezigulini ezinesithuthwane esingazweli ekwelashweni: isivivinyo sokungenelela esinelebula evulekile. ILancet Neurol. 2016 Mar; 15: 270-8. Buka okungaqondakali.
  71. I-97021 Jadoon KA, iRatcliffe SH, iBarrett DA, et al. Ukusebenza nokuphepha kwe-cannabidiol ne-tetrahydrocannabivarin kumapharamitha we-glycemic ne-lipid ezigulini ezinesifo sikashukela sohlobo lwe-2: isifundo esilawulwa ngokungahleliwe, esimpumputhe, esilawulwa yi-placebo, esifanayo. Ukunakekelwa yisifo sikashukela. 2016 Okthoba; 39: 1777-86. Buka okungaqondakali.
  72. UGofshteyn JS, uWilfong A, uDevinsky O, et al. I-Cannabidiol njengokwelashwa okungaba khona kwesifo sokuwa esihlobene nokutheleleka okutheleleka (i-FIRES) ezigabeni ezinzima nezihlala njalo. J Ingane Neurol. 2017 uJan; 32: 35-40. Buka okungaqondakali.
  73. UHess EJ, Moody KA, Geffrey AL, et al. I-Cannabidiol njengokwelashwa okusha kwesifo sokuwa okungazweli emthini ku-tuberous sclerosis complex. Isifo sokuwa. 2016 Okthoba; 57: 1617-24.
  74. UGaston TE, uBebin EM, umsiki GR, uLiu Y, uSzaflarski JP; Uhlelo lwe-UAB CBD. Ukusebenzisana phakathi kwe-cannabidiol nezidakamizwa ezisetshenziswa kakhulu zokulwa nesifo sokuwa. Isifo sokuwa. 2017 Septhemba; 58: 1586-92. Buka okungaqondakali.
  75. UDevinsky O, uCross JH, uLaux L, et al. Ukuhlolwa kwe-cannabidiol ngokuhlaselwa okungazweli emthini ku-Dravet Syndrome. N Engl J Med. 2017 uMeyi 25; 376: 2011-2020. Buka okungaqondakali.
  76. UBonn-Miller MO, uLoflin MJE, uThomas BF, uMarcu JP, uHyke T, uVandrey R. Ukubhala ngokunemba kokukhishwa kwe-cannabidiol okuthengiswa online. I-JAMA 2017 Nov; 318: 1708-9. Buka okungaqondakali.
  77. UMalfait AM, uGallily R, uSumariwalla PF, et al. I-non-psychoactive cannabis-constituent cannabidiol iyi-oral anti-arthritic therapeutic ku-murine collagen eyenziwe i-arthritis. I-Proc Natl Acad Sci USA 2000; 97: 9561-6. Buka okungaqondakali.
  78. IFormukong EA, u-Evans AT, u-Evans FJ. Umsebenzi we-analgesic nowokulwa nokuvuvukala wezakhi zeCannabis sativa L. Ukuvuvukala 1988; 12: 361-71. Buka okungaqondakali.
  79. UValvassori SS, u-Elias G, de Souza B, et al. Imiphumela ye-cannabidiol ekukhiqizeni ukucindezeleka okwenziwe nge-amphetamine kwimodeli yezilwane ye-mania. UJ Psychopharmacol 2011; 25: 274-80. Buka okungaqondakali.
  80. U-Esposito G, uScuderi C, uSavani C, et al. I-Cannabidiol ku-vivo ifiphaza i-beta-amyloid eyenziwe nge-neuroinfigueation ngokucindezela i-IL-1beta ne-iNOS expression. UBr J Pharmacol 2007; 151: 1272-9. Buka okungaqondakali.
  81. U-Esposito G, uDe Filippis D, uMaiuri MC, et al. ICannabidiol inhibit inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons ngokusebenzisa i-p38 MAP kinase nokubandakanyeka kwe-NF-kappaB. INeurosci Lett 2006; 399 (1-2): 91-5. Buka okungaqondakali.
  82. U-Iuvone T, u-Esposito G, uDe Filippis D, et al. I-Cannabidiol: umuthi omusha othembisayo wezifo ze-neurodegenerative? I-CNS Neurosci Ther 2009; 15: 65-75. Buka okungaqondakali.
  83. I-Bisogno T, i-Di Marzo Y. Indima yohlelo lwe-endocannabinoid ku-Alzheimer's's disease: amaqiniso nokucabanga. ICurr Pharm Des 2008; 14: 2299-3305. Buka okungaqondakali.
  84. I-Zuardi AW. I-Cannabidiol: kusuka ku-cannabinoid engasebenzi kuya kumuthi onezenzo eziningi. UMfu Bras Psiquiatr 2008; 30: 271-80. Buka okungaqondakali.
  85. Izzo AA, Borelli F, Capasso R, et al. Izitshalo ezingama-non-psychotropic plant cannabinoids: amathuba amasha okwelapha avela emthini wasendulo. Amathrendi Pharmacol Sci 2009; 30: 515-27. Buka okungaqondakali.
  86. I-Booz GW. I-Cannabidiol njengecebo elivelayo lokwelapha lokunciphisa umthelela wokuvuvukala ekucindezelekeni kwe-oxidative. I-Radic Biol Med yamahhala ngo-2011; 51: 1054-61. Buka okungaqondakali.
  87. U-Pickens JT. Umsebenzi wokulalisa insangu maqondana nokuqukethwe kwawo kwe-delta’-trans-tetrahydrocannabinol kanye ne-cannabidiol. UBr J Pharmacol 1981; 72: 649-56. Buka okungaqondakali.
  88. Monti JM. Imiphumela efana ne-Hypnotic ye-cannabidiol kumagundane. I-Psychopharmacology (Berl) 1977; 55: 263-5. Buka okungaqondakali.
  89. UKarller R, iTurkanis SA. Subacute ukwelashwa kwe-cannabinoid: umsebenzi we-anticonvulsant kanye nokuhoxiswa kokuthakazelisa kumagundane. UBr J Pharmacol 1980; 68: 479-84. Buka okungaqondakali.
  90. UKarller R, uCely W, iTurkanis SA. Umsebenzi we-anticonvulsant we-cannabidiol ne-cannabinol. Impilo Sci 1973; 13: 1527-31. Buka okungaqondakali.
  91. I-Consroe PF, i-Wokin AL. Ukusebenzisana kwe-Anticonvulsant kwe-cannabidiol ne-ethosuximide kumagundane. UJ Pharm Pharmacol 1977; 29: 500-1. Buka okungaqondakali.
  92. I-Consroe P, i-Wolkin A. Ukuqhathaniswa kwezidakamizwa ze-Cannabidiol-antiepilpetic kanye nokusebenzisana ekubanjweni kokuhlolwa okwenziwe ngamagundane. UJ Pharmacol Exp Ther 1977; 201: 26-32. Buka okungaqondakali.
  93. UCarlini EA, uLeite JR, uTannhauser M, uBerardi AC. Incwadi: I-Cannabidiol ne-Cannabis sativa kukhishwa ukuvikela amagundane namagundane kuma-convulsive agents. UJ Pharm Pharmacol 1973; 25: 664-5. Buka okungaqondakali.
  94. UCryan JF, uMarkou A, uLucki I. Ukuhlola umsebenzi we-antidepressant kumagundane: intuthuko yakamuva nezidingo zesikhathi esizayo. Amathrendi Pharmacol Sci 2002; 23: 238-45. Buka okungaqondakali.
  95. U-El-Alfy AT, u-Ivey K, uRobinson K, et al. Umphumela ofana ne-antidepressant we-delta9-tetrahydrocannabinol namanye ama-cannabinoids ahlukaniswe ne-Cannabis sativa L. Pharmacol Biochem Behav 2010; 95: 434-42. Buka okungaqondakali.
  96. I-Resstel LB, iTavares RF, iLisboa SF, et al. Ama-5-HT1A receptors abandakanyekile ekunciphiseni okwenziwe yi-cannabidiol kwezimpendulo zokuziphatha nezenhliziyo ekucindezelekeni okukhulu kumagundane. UBr J Pharmacol 2009; 156: 181-8. Buka okungaqondakali.
  97. IGranjeiro EM, iGomes FV, ​​iGuimaraes FS, et al. Imiphumela yokuphathwa kwangaphakathi kwe-cannabidiol ekuphenduleni kwenhliziyo nokuziphatha ekucindezelekeni okukhulu kokuzibamba. I-Pharmacol Biochem Behav 2011; 99: 743-8. Buka okungaqondakali.
  98. UMurillo-Rodriguez E, uMillan-Aldaco D, uPalomero-Rivero M, et al. I-Cannabidiol, indawo yeCannabis sativa, ihlehlisa ukulala kumagundane. FEBS Lett 2006; 580: 4337-45. Buka okungaqondakali.
  99. UDe Filippis D, u-Esposito G, uCirillo C, et al. I-Cannabidiol inciphisa ukuvuvukala kwamathumbu ngokulawulwa kwe-axis ye-neuroimmune. Ama-PLoS One 2011; 6: e28159. Buka okungaqondakali.
  100. UBhattacharyya S, uFusar-Poli P, uBorgwardt S, et al. Ukushintshashintsha komsebenzi we-mediotemporal kanye ne-ventrostriatal kubantu yi-Delta9-tetrahydrocannabinol: isisekelo se-neural semiphumela yeCannabis sativa ekufundeni nasengqondweni. I-Arch Gen Psychiatry 2009; 66: 442-51. Buka okungaqondakali.
  101. UDalton WS, uMartz R, uLemberger L, et al. Ithonya le-cannabidiol emiphumeleni ye-delta-9-tetrahydrocannabinol. I-Clin Pharmacol Ther 1976; 19: 300-9. Buka okungaqondakali.
  102. IGuimaraes VM, iZuardi AW, iDel Bel EA, iGuimaraes FS. I-Cannabidiol ikhulisa ukubonakaliswa kwe-Fos kuma-nucleus accumbens kepha hhayi ku-dorsal striatum. ILife Sci 2004; 75: 633-8. Buka okungaqondakali.
  103. IMoreira FA, iGuimaraes FS. I-Cannabidiol ivimbela i-hyperlocomotion ebangelwa izidakamizwa ze-psychomimetic kumagundane. I-Eur J Pharmacol 2005; 512 (2-3): 199-205. Buka okungaqondakali.
  104. Isikhathi eside LE, Chesworth R, Huang XF, et al. Ukuqhathanisa kokuziphatha kwe-Delta9-tetrahydrocannabinol enamandla futhi engapheli ne-cannabidiol ku-C57BL / 6JArc amagundane. I-Int J Neuropsychopharmacol 2010; 13: 861-76. Buka okungaqondakali.
  105. UZuardi AW, uRodriguez JA, uCunha JM. Imiphumela ye-cannabidiol kumamodeli wezilwane ukuqagela komsebenzi we-antipsychotic. I-Psychopharmacology (Berl) 1991; 104: 260-4. Buka okungaqondakali.
  106. IMalone DT, uJongejan D, Taylor DA. I-Cannabidiol iguqula ukuncipha kokuxhumana komphakathi okukhiqizwa yi-low low Delta-tetrahydrocannabinol kumagundane. I-Pharmacol Biochem Behav 2009; 93: 91-6. Buka okungaqondakali.
  107. ISchubart CD, uSommer IE, uFusar-Poli P, et al. I-Cannabidiol njengokwelashwa okungenzeka kube yi-psychosis. I-Eur Neuropsychopharmacol 2014; 24: 51-64. Buka okungaqondakali.
  108. ICampos AC, iMoreira FA, iGomes FV, ​​et al. Izindlela eziningi ezihilelekile ekutholakaleni kwe-spectrum enkulu ye-cannabidiol ezinkingeni zengqondo. IPhilos Trans R Soc Lond B Biol Sci 2012; 367: 3364-78. Buka okungaqondakali.
  109. UFusar-Poli P, u-Allen P, uBhattacharyya S, et al. Ukushintshashintsha kokuxhuma okusebenzayo ngenkathi kucutshungulwa ngokomzwelo yiDelta 9-tetrahydrocannabinol ne-cannabidiol. I-Int J Neuropsychopharmacol 2010; 13: 421-32. Buka okungaqondakali.
  110. ICasarotto PC, Gomes FV, ​​Resstel LB, Guimaraes FS. Umphumela we-Cannabidiol inhibitory ekuziphatheni kokungcwaba imabula: ukubandakanyeka kwama-receptors e-CB1. I-Behav Pharmacol 2010; 21: 353-8. Buka okungaqondakali.
  111. U-Uribe-Marino A, uFrancisco A, uCastiblanco-Urbina MA, et al. Imiphumela yokulwa ne-anti-aversive ye-cannabidiol ekuziphatheni okwenziwe ngaphakathi kokwesaba okukhishwe yimodeli yokuziphatha kokuhlaselwa ngokwesaba okususelwa kudlame vs inyoka yasendle i-Epicrate cenchria crassus yokulwa neparadigm. I-Neuropsychopharmacology 2012; 37: 412-21. Buka okungaqondakali.
  112. ICampos AC, iGuimaraes FS. Ukwenza kusebenze ama-5HT1A receptors axhumanisa imiphumela ye-anxiolytic ye-cannabidiol kumodeli ye-PTSD. I-Behav Pharmacol 2009; 20: S54.
  113. I-Resstel LB, i-Joca SR, i-Moreira FA, et al. Imiphumela ye-cannabidiol ne-diazepam kuzimpendulo zokuziphatha nezenhliziyo ezibangelwa ukwesaba okunemibandela yesimo kumagundane. I-Behav Brain Res 2006; 172: 294-8. Buka okungaqondakali.
  114. UMoreira FA, i-Aguiar DC, iGuimaraes FS. Umphumela ofana ne-anxiolytic we-cannabidiol ekuhlolweni kwempikiswano ye-Vogel. IProg Neuropsychopharmacol Biol Psychiatry 2006; 30: 1466-71. Buka okungaqondakali.
  115. U-Onaivi ES, Green MR, Martin BR. Ukuchazwa kwamakhemikhali kwama-cannabinoids ku-maze ephakeme ephakeme. UJ Pharmacol Exp Ther 1990; 253: 1002-9. Buka okungaqondakali.
  116. IGuimaraes FS, uChairetti TM, iGraeff FG, iZuardi AW. Umphumela wokukhathazeka we-cannabidiol ku-plus-maze ephakeme. I-Psychopharmacology (Berl) 1990; 100: 558-9. Buka okungaqondakali.
  117. UMagen I, u-Avraham Y, u-Ackerman Z, et al. I-Cannabidiol ithuthukisa ukukhubazeka kwengqondo nokuqonda kwezimoto kumagundane ane-bile duct ligation. UJ Hepatol 2009; 51: 528-34. Buka okungaqondakali.
  118. URajesh M, uMukhopadhyay P, uBatkai S, et al. I-Cannabidiol inciphisa ukukhubazeka kwenhliziyo, ukucindezeleka okwenziwe nge-oxidative, i-fibrosis, nokuvuvukala kanye nokufa kweseli okukhombisa izindlela ku-cardiomyopathy yesifo sikashukela. UJ Am Coll Cardiol 2010; 56: 2115-25. Buka okungaqondakali.
  119. U-El-Remessy AB, uKhalifa Y, u-Ola S, et al. I-Cannabidiol ivikela ama-neuron we-retina ngokulondoloza umsebenzi we-glutamine synthetase kwisifo sikashukela. I-Mol Vis 2010; 16: 1487-95. Buka okungaqondakali.
  120. U-El-Remessy AB, u-Al-Shabrawey M, uKhalifa Y, et al. I-Neuroprotective kanye ne-retina barriers-ekulondolozeni imiphumela ye-cannabidiol kusifo sikashukela sokuhlola. NginguJ J Pathol 2006; 168: 235-44. Buka okungaqondakali.
  121. URajesh M, uMukhopadhyay P, uBatkai S, et al. I-Cannabidiol inciphisa i-glucose ephezulu-ikhuthaza ukuphendula kokuvuvukala kwamaseli endothelial nokuphazamiseka kwesithiyo. NginguJ J Physiol Heart Circ Physiol 2007; 293: H610-H619. Buka okungaqondakali.
  122. IToth CC, uJedrzejewski NM, u-Ellis CL, uFrey WH. Ukushintshashintsha kwe-Cannabinoid-mediated of neuropathic pain and microglial accumulation on a model of murine type 1 diabetic peripheral neuropathic pain. I-Mol Pain 2010; 6: 16. Buka okungaqondakali.
  123. U-Aviello G, uRomano B, uBorrelli F, et al. Imiphumela ye-Chemopreventive ye-non-psychotropic phytocannabinoid cannabidiol kumdlavuza we-colon wokuhlola. UJ Mol Med (Berl) 2012; 90: 925-34. Buka okungaqondakali.
  124. ULee CY, Wey SP, uLiao MH, et al. Ucwaningo lokuqhathanisa nge-apoptosis eyenziwe nge-cannabidiol kuma-murine thymocytes namaseli we-EL-4 thymoma. I-Int Immunopharmacol 2008; 8: 732-40. Buka okungaqondakali.
  125. UMassi P, uValenti M, uVaccani A, et al. I-5-Lipoxygenase ne-anandamide hydrolase (FAAH) ixhumanisa umsebenzi we-antitumor we-cannabidiol, i-cannabinoid engeyona eyengqondo. UJ Neurochem 2008; 104: 1091-100. Buka okungaqondakali.
  126. UValenti M, Massi P, Bolognini D, et al. I-Cannabidiol, i-non-psychoactive cannabinoid compound ivimbela ukufuduka kwamaseli we-glioma kanye nokuhlasela. I-34th National Congress ye-Italy Society of Pharmacology 2009.
  127. UTorres S, uLorente M, uRodriguez-Fornes F, et al. Ukwelashwa okuhlanganisiwe kwangaphambi kokuchazwa kwama-cannabinoids ne-temozolomide ngokumelene ne-glioma. I-Mol Cancer Ther 2011; 10: 90-103. Buka okungaqondakali.
  128. UJacobsson SO, uRongard E, uStridh M, et al. Imiphumela encike kuSerum ye-tamoxifen kanye ne-cannabinoids ekusebenzeni kweseli le-C6 glioma. I-Biochem Pharmacol 2000; 60: 1807-13. Buka okungaqondakali.
  129. UShrivastava A, u-PM Kuzontkoski, uGroopman JE, uPrasad A. Cannabidiol ukhuthaza ukufa kwamaseli okuhleliwe kumaseli womdlavuza webele ngokuxhumanisa inkulumo ephambene phakathi kwe-apoptosis ne-autophagy. I-Mol Cancer Ther 2011; 10: 1161-72. Buka okungaqondakali.
  130. UMcAllister SD, uMurase R, uChristian RT, et al. Izindlela ezilamula imiphumela ye-cannabidiol ekwehliseni ukwanda kwesifo somdlavuza webele, ukuhlasela, kanye ne-metastasis. Ukwelashwa Kwe-Cancer Res 2011; 129: 37-47. Buka okungaqondakali.
  131. UMcAllister SD, uChristian RT, iPhalamende laseHorowitz, et al. I-Cannabidiol njenge-inhibitor yenoveli ye-Id-1 expression expression kumaseli womdlavuza webele onolaka. I-Mol Cancer Ther 2007; 6: 2921-7. Buka okungaqondakali.
  132. ULigresti A, uMoriello AS, uStarowicz K, et al. Umsebenzi we-Antitumor wezitshalo ezingama-cannabinoids ngokugcizelela umphumela we-cannabidiol ku-carcinoma yebele lomuntu. UJ Pharmacol Exp Ther 2006; 318: 1375-87. Buka okungaqondakali.
  133. UMassi P, uSolinas M, uCinquina V, uParolaro D.Cannabidiol njengomuthi onamandla wokulwa nomdlavuza. UBr J Clin Pharmacol 2013; 75: 303-12. Buka okungaqondakali.
  134. I-Schubart CD, iSommer IE, van Gastel WA, et al. I-cannabis enokuqukethwe okuphezulu kwe-cannabidiol ihlotshaniswa nokuhlangenwe nakho okumbalwa kwengqondo. ISchizophr Res 2011; 130 (1-3): 216-21. Buka okungaqondakali.
  135. U-Englund A, uMorrison PD, uNottage J, et al. I-Cannabidiol ivimbela i-THC-ephakanyiswe izimpawu ze-paranoid nokukhubazeka kwememori ethembeke ku-hippocampal. J I-Psychopharmacol 2013; 27: 19-27. Buka okungaqondakali.
  136. UDevinsky O, uCilio MR, uCross H, et al. I-Cannabidiol: i-pharmacology kanye nendima engaba khona ekwelashweni kwesifo sokuwa nezinye izifo ze-neuropsychiatric. Isifo sokuwa 2014; 55: 791-802. Buka okungaqondakali.
  137. I-Serpell MG, i-Notcutt W, i-Collin C. Ukusetshenziswa kwesikhathi eside kwe-Sativex: isivivinyo esinelebuli evulekile ezigulini ezine-spasticity ngenxa ye-multiple sclerosis. UJ Neurol 2013; 260: 285-95. Buka okungaqondakali.
  138. UNotcutt W, uLangford R, uDavies P, et al. Iqembu elilawulwa yi-placebo, elihambisanayo, ukufundwa kokuhoxiswa okungahleliwe kwezihloko ezinezimpawu zokuqina ngenxa ye-multiple sclerosis ethola iSativex yesikhathi eside (nabiximols). IMult Scler 2012; 18: 219-28. Buka okungaqondakali.
  139. UBrady CM, uDasGupta R, uDalton C, et al. Ucwaningo oluvulekile lwelebula lokukhishwa okususelwa ku-cannabis lokungasebenzi kahle kwesinye ku-advanced multiple sclerosis. IMult Scler 2004; 10: 425-33. Buka okungaqondakali.
  140. UKavia RB, uDe Ridder D, uConstantinescu CS, et al. Isivivinyo esilawulwa ngokungahleliwe seSativex ukwelapha ukusebenza ngokweqile kwesifo sokuqina kwemithambo IMult Scler 2010; 16: 1349-59. Buka okungaqondakali.
  141. UWade DT, PM Makela PM, House H, et al. Ukusetshenziswa kwesikhathi eside kokwelashwa okususelwa ku-cannabis ekuphambaneni nezinye izimpawu ku-multiple sclerosis. IMult Scler 2006; 12: 639-45. Buka okungaqondakali.
  142. UNovotna A, Mares J, uRatcliffe S, et al. I-randomized, blind-blind-controlled, placebo-controlled group, parallel-group, ukucebisa-design design ye-nabiximols * (Sativex), njenge-add-on therapy, ezifundweni ezine-reflexory spasticity ezibangelwa yi-multiple sclerosis. I-Eur J Neurol 2011; 18: 1122-31. Buka okungaqondakali.
  143. Sibutsetelo. Iwebhusayithi ye-GW Pharmaceuticals.Itholakala ku: http://www.gwpharm.com/about-us-overview.aspx. Kufinyelelwe: Meyi 31, 2015.
  144. I-Cannabidiol Manje Ikhombisa Izithasiselo Zokudla. Iwebhusayithi Yemithi Yemvelo. https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements.aspx. (Kufinyelelwe ngoMeyi 31, 2015).
  145. UZuardi AW, uCosme RA, uGraeff FG, uGuimaraes FS. Imiphumela ye-ipsapirone ne-cannabidiol ekukhathazekeni kokuhlola komuntu. J I-Psychopharmacol 1993; I-7 (1 Suppl): 82-8. Buka okungaqondakali.
  146. Eighty EG, Fentiman AF Jr, Foltz RL. Ama-metabolites agcinwe isikhathi eside we-delta9- ne-delta8-tetrahydrocannabinols akhonjwe njengama-conjugates enoveli anamafutha. I-Res Commun Chem Pathol Pharmacol 1976; 14: 13-28. Buka okungaqondakali.
  147. USamara E, uBialer M, uMechoulam R. Pharmacokinetics we-cannabidiol ezinjeni. Izidakamizwa ze-Metab Dispos 1988; 16: 469-72. Buka okungaqondakali.
  148. I-Consroe P, iSandyk R, iSnider SR. Vula ukuhlolwa kwelebuli ye-cannabidiol ezinkingeni zokunyakaza ze-dystonic. I-Int J Neurosci 1986; 30: 277-82. Buka okungaqondakali.
  149. UCrippa JA, uDerenusson GN, uFerrari TB, et al. Isisekelo se-Neural semiphumela ye-anxiolytic ye-cannabidiol (i-CBD) ekuphazamisweni kokukhathazeka komphakathi okujwayelekile: umbiko wokuqala. UJ Psychopharmacol 2011; 25: 121-30. Buka okungaqondakali.
  150. I-Bornheim LM, i-Everhart ET, uLi J, uCorreia MA. Ukuchazwa kokungasebenzi kwe-cytochrome P450 ye-cannabidiol. I-Biochem Pharmacol 1993; 45: 1323-31. Buka okungaqondakali.
  151. UHarvey DJ. Ukuncela, ukusabalalisa, kanye ne-biotransformation yama-cannabinoids. Insangu Nomuthi. 1999; 91-103.
  152. UYamaori S, Ebisawa J, Okushima Y, et al. Ukuvinjelwa okunamandla kwe-cytochrome yomuntu i-P450 3A isoforms yi-cannabidiol: indima yamaqembu e-phenolic hydroxyl eqenjini le-resorcinol. ILife Sci 2011; 88 (15-16): 730-6. Buka okungaqondakali.
  153. I-Yamaori S, i-Okamoto Y, i-Yamamoto I, i-Watanabe K. Cannabidiol, i-phytocannabinoid enkulu, njenge-inhibitor enamandla ye-CYP2D6. Izidakamizwa ze-Metab Dispos 2011; 39: 2049-56. Buka okungaqondakali.
  154. I-Yamaori S, i-Maeda C, i-Yamamoto I, i-Watanabe K. Ukwahlukana okuhlukile kwe-cytochrome yomuntu i-P450 2A6 ne-2B6 ngama-phytocannabinoids amakhulu. I-Forensic Toxicol 2011; 29: 117-24.
  155. I-Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Ukuchazwa kwama-phytocannabinoids amakhulu, i-cannabidiol ne-cannabinol, njenge-isoform-selective potent inhibitors yama-enzyme e-CYP1 womuntu. I-Biochem Pharmacol 2010; 79: 1691-8. Buka okungaqondakali.
  156. UZuardi AW, Crippa JA, Hallak JE, et al. I-Cannabidiol yokwelashwa kwengqondo ku-Parkinson's disease. UJ Psychopharmacol 2009; 23: 979-83. Buka okungaqondakali.
  157. UMorgan CJ, uDas RK, uJoye A, et al. I-Cannabidiol inciphisa ukusetshenziswa kukagwayi kubantu ababhemayo kagwayi: ukutholwa kokuqala. Umlutha Behav 2013; 38: 2433-6. Buka okungaqondakali.
  158. I-Pertwee RG. I-CB1 ne-CB2 receptor pharmacology yezitshalo ezintathu ze-cannabinoids: i-delta9-tetrahydrocannabinol, i-cannabidiol ne-delat9-tetrahydrocannabivarin. UBr J Pharmacol 2008; 153: 199-215. Buka okungaqondakali.
  159. ILeweke FM, uKranaster L, uPahlisch F, et al. Ukusebenza kwe-cannabidiol ekwelapheni i-schizophrenia - indlela yokuhumusha. ISchizophr Bull 2011; 37 (iSuppl 1): 313.
  160. ILeweke FM, uPiomelli D, uPahlisch F, et al. I-Cannabidiol ithuthukisa ukusayina kwe-anandamide futhi inciphise izimpawu zengqondo ze-schizophrenia. Humusha i-Psychiatry 2012; 2: e94. Buka okungaqondakali.
  161. UCarroll CB, uBain PG, uTeare L, et al. I-Cannabis ye-dyskinesia esifo se-Parkinson: isifundo se-crossover esingaboni kahle. I-Neurology 2004; 63: 1245-50. Buka okungaqondakali.
  162. IBergamaschi MM, iQueiroz RH, uChagas MH, et al. I-Cannabidiol inciphisa ukukhathazeka okubangelwa ukukhuluma komphakathi okufanisiwe kwiziguli zokwelashwa-na pve social phobia. I-Neuropsychopharmacology 2011; 36: 1219-26. Buka okungaqondakali.
  163. UZuardi AW, Crippa JA, Hallak JE, et al. I-Cannabidiol, indawo ye-Cannabis sativa, njengesidakamizwa sokulwa ne-psychotic. I-Braz J Med Biol Res 2006; 39: 421-9. Buka okungaqondakali.
  164. UYadav V, uBever C Jr, uBowen J, et al. Isifinyezo somhlahlandlela osuselwa ebufakazini: umuthi ohambisanayo kanye nokunye kwi-multiple sclerosis: umbiko wekomidi elincane lokuthuthukiswa komhlahlandlela weAmerican Academy of Neurology. Neurology. 2014; 82: 1083-92. Buka okungaqondakali.
  165. UTrembly B, uSherman M. Ucwaningo lwemitholampilo engaboni kabili ye-cannabidiol njenge-anticonvulsant yesibili. Ingqungquthela Yomhlaba Wonke Yensangu ye-Marijuana '90 yeCannabis kanye ne-Cannabinoids 1990; 2: 5.
  166. Srivastava, M. D., Srivastava, B. I., noBrouhard, B. Delta9 tetrahydrocannabinol kanye ne-cannabidiol bashintsha ukukhiqizwa kwe-cytokine ngamaseli omzimba womuntu. I-Immunopharmacology 1998; 40: 179-185. Buka okungaqondakali.
  167. UCunha, JM, Carlini, EA, Pereira, AE, Ramos, OL, Pimentel, C., Gagliardi, R., Sanvito, WL, Lander, N., noMechoulam, R. Ukuphathwa okungapheli kwe-cannabidiol kumavolontiya anempilo kanye neziguli ezinesifo sokuwa . Ikhemisi 1980; 21: 175-185. Buka okungaqondakali.
  168. UCarlini EA, uCunha JM. Imiphumela ye-hypnotic ne-antiepileptic ye-cannabidiol. UJ Clin Pharmacol 1981; 21 (8-9 Suppl): 417S-27S. Buka okungaqondakali.
  169. UZuardi, A. W., Shirakawa, I., Finkelfarb, E., noKarniol, I. G. Isenzo se-cannabidiol ekukhathazeni nakweminye imiphumela eyenziwe yi-delta 9-THC ezifundweni ezijwayelekile. I-Psychopharmacology (Berl) 1982; 76: 245-250. Buka okungaqondakali.
  170. Ames, F. R. noCridland, S. Umphumela we-Anticonvulsant we-cannabidiol. I-S.Afr.Med.J. 1-4-1986; 69:14. Buka okungaqondakali.
  171. U-Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., noHollister, L. E. I-single-dose kinetics ye-deuterium enelebuli ye-cannabidiol kumuntu ngemuva kokubhema nokuphathwa kwemithambo. I-Biomed.Environ Mass Spectrom. 1986; 13: 77-83. Buka okungaqondakali.
  172. UWade, D.T, uCollin, uC., UStott, uC, noDuncombe, uP. Meta-ukuhlaziywa kokusebenza nokuphepha kweSativex (nabiximols), ekuphakameni kwabantu abane-multiple sclerosis. I-Mult.Scler. 2010; 16: 707-714. Buka okungaqondakali.
  173. UCollin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, I ., Zapletalova, O., Pikova, J., no-Ambler, Z. Ucwaningo lwe-Sativex oluyimpumputhe, olungenangqondo, olulawulwa yi-placebo, ngezihloko ezinezimpawu zokuphamba ngenxa ye-multiple sclerosis. Neurol.Res. 2010; 32: 451-459. Buka okungaqondakali.
  174. UCrippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., noFusar-Poli, P. Insangu nokukhathazeka: ukubuyekeza okubucayi kobufakazi. Hum. IPsychopharmacol. U-2009; 24: 515-523. Buka okungaqondakali.
  175. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., noSchram, K. Isivivinyo somtholampilo esilawulwayo se-cannabidiol kwisifo sikaHuntington. I-Pharmacol Biochem.I-Behav. 1991; 40: 701-708. Buka okungaqondakali.
  176. UHarvey, D. J., Samara, E., noMechoulam, R. Ukuqhathanisa imetabolism ye-cannabidiol enjeni, egundaneni nasemuntwini. I-Pharmacol Biochem.I-Behav. 1991; 40: 523-532. Buka okungaqondakali.
  177. UCollin, C., Davies, P., Mutiboko, I. K., noRatcliffe, S. Isivivinyo esilawulwa ngokungahleliwe semithi esuselwa ku-cannabis ekuphakameni okubangelwa yi-multiple sclerosis. U-Eur. J. Neurol. 2007; 14: 290-296. Buka okungaqondakali.
  178. UMassi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., noParolaro, D. I-cannabidiol engeyona eye-psychoactive ibangela ukwenziwa kwe-caspase kanye nengcindezi ye-oxidative kumaseli e-glioma womuntu. Iseli Mol. Life Sci. 2006; 63: 2057-2066. Buka okungaqondakali.
  179. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., noGallily, R. Cannabidiol kwehlisa izehlakalo zesifo sikashukela kumagundane esifo sikashukela angakhuluphele. Ukuzimela okuzenzakalelayo 2006; 39: 143-151. Buka okungaqondakali.
  180. I-Watzl, B., i-Scuderi, i-P, ne-Watson, i-R.R. Izakhi zensangu zikhuthaza uketshezi kwegazi lomzimba lenyukliya le-interferon-gamma kanye nokucindezela i-interleukin-1 alpha in vitro. I-Int J Immunopharmacol. 1991; 13: 1091-1097. Buka okungaqondakali.
  181. I-Consroe, P., Kennedy, K., ne-Schram, K. Ukuhlolwa kwe-plasma cannabidiol nge-capillary gas chromatography / ion trap mass spectroscopy elandela ukuphathwa komlomo okuphindaphindwayo kwansuku zonke kubantu. I-Pharmacol Biochem.I-Behav. 1991; 40: 517-522. Buka okungaqondakali.
  182. UBarnes, M. P. Sativex: ukusebenza komtholampilo nokubekezelela ekwelapheni izimpawu ze-multiple sclerosis nobuhlungu be-neuropathic. Isazi.Opin.I-Pharmacotherother. 2006; 7: 607-615. Buka okungaqondakali.
  183. UWade, D.T, Makela, P., Robson, P., House, H., noBateman, C. Ingabe ukukhishwa okwenziwe nge-cannabis kwezokwelapha kunemiphumela ejwayelekile noma ethize kwizimpawu ze-multiple sclerosis? Ucwaningo olulawulwa kabili, olungahleliwe, olulawulwa yi-placebo ezigulini eziyi-160. I-Mult.Scler. 2004; 10: 434-441. Buka okungaqondakali.
  184. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., no-Izzo, umphumela we-AA Neuroprotective we-cannabidiol, ingxenye engeyona eyengqondo evela ku-Cannabis sativa, ku-beta-amyloid-eyenziwe ubuthi kumaseli we-PC12. J Neurochem. 2004; 89: 134-141. Buka okungaqondakali.
  185. UMassi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., noParolaro, D. Imiphumela ye-Antitumor ye-cannabidiol, i-cannabinoid engasebenzi, emigqeni yeseli ye-glioma. J Pharmacol Exp. Manje. 2004; 308: 838-845. Buka okungaqondakali.
  186. UCrippa, JA, Zuardi, AW, Garrido, GE, Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, PM, Hallak, JE, McGuire, PK, noFoho, Busatto G. Imiphumela ye-cannabidiol (i-CBD) ekugelezeni kwegazi lobuchopho besifunda. I-Neuropsychopharmacology 2004; 29: 417-426. Buka okungaqondakali.
  187. UWade, D.T., Robson, P., House, H., Makela, P., no-Aram, J. Ucwaningo lokuqala olulawulwayo lokuthola ukuthi ngabe ukukhishwa kwe-cannabis yesitshalo sonke kungathuthukisa yini izimpawu ze-neurogenic ezingenakulinganiswa. Umtholampilo Ukuvuselelwa. 2003; 17: 21-29. Buka okungaqondakali.
  188. UCovington TR, et al. Incwajana Yezidakamizwa Ezingabhalisiwe. Umhla ka-11. IWashington, DC: I-American Pharmaceutical Association, 1996.
Kugcine ukubuyekezwa - 12/18/2020

Inconyelwe Kuwe

Izindlela Ezi-16 Ezilula Zokudla Amafayibha Angaphezulu
Umsoco

Izindlela Ezi-16 Ezilula Zokudla Amafayibha Angaphezulu

Ukuthola i-fiber eyanele kubalulekile empilweni yakho.Kokunye, kunganciphi a ukuqunjelwa futhi ku ize ekwehli eni i i indo kanye nokugcinwa.Kunganciphi a namazinga e-chole terol, kanye nengozi yakho y...
Abafana Bayeka Nini Ukukhula?
Impilo

Abafana Bayeka Nini Ukukhula?

Ingabe abafana bayakhula eminyakeni yabo yobu ha kamuva?Abafana babonakala bekhula ngamanani amangali ayo, okungenza noma yimuphi umzali azibuze: Abafana bayeka nini ukukhula? NgokweNational Health e...